Literature DB >> 27885376

High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound.

Rosario Ibáñez-Bosch1,2, Juliana Restrepo-Velez3, Miguel Medina-Malone3, Laura Garrido-Courel3, Inmaculada Paniagua-Zudaire3, Eduardo Loza-Cortina3.   

Abstract

Analyse the presence of subclinical atherosclerosis in psoriatic arthritis patients (PsA). A cross-sectional study of 53 patients with PsA and 53 controls matched for age and sex was designed. Carotid intima-media thickness (IMT) and the presence of carotid plaques (CP) were assessed with carotid ultrasound. Data on cardiovascular (CV) risk factors were collected. Patients with PsA had a higher prevalence rate of obesity and tobacco smoking. CP were detected more frequently in patients with PsA than in controls with an OR of 4.15, 95% CI 1.4-12.1, which adjusted for smoking and those with history of CV disease gave an OR of 3.9, 95% CI 1.2-12.7, p = 0.026. Carotid IMT was significantly higher in patients with PsA adjusted for age and tobacco smoking. According to ultrasound data, 30.2% of patients with PsA had carotid atherosclerosis (presence of CP and/or carotid IMT > 0.90 mm) compared with 9.4% of controls. The SCORE index (Systematic Coronary Risk Evaluation) underestimated the CV risk in these patients: most patients with CP had an intermediate CV risk. According to carotid ultrasound data, PsA patients have a high prevalence of subclinical atherosclerosis. These results support the importance of screening for CV risk and to include carotid ultrasound in CV prevention strategies in these patients.

Entities:  

Keywords:  Cardiovascular disease; Carotid ultrasound; Psoriatic arthritis

Mesh:

Year:  2016        PMID: 27885376     DOI: 10.1007/s00296-016-3617-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

1.  Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)).

Authors:  G Belcaro; A N Nicolaides; G Ramaswami; M R Cesarone; M De Sanctis; L Incandela; P Ferrari; G Geroulakos; A Barsotti; M Griffin; S Dhanjil; M Sabetai; M Bucci; G Martines
Journal:  Atherosclerosis       Date:  2001-06       Impact factor: 5.162

2.  Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.

Authors:  Baris Yilmazer; Tayfun Sahin; Berrin Öztaş Unlu; Hale Maral Kir; Ayse Cefle
Journal:  Rheumatol Int       Date:  2015-02-11       Impact factor: 2.631

3.  Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation.

Authors:  L-S Tam; B Tomlinson; T T-W Chu; M Li; Y-Y Leung; L-W Kwok; T K Li; T Yu; Y-E Zhu; K-C Wong; E W-L Kun; E K Li
Journal:  Rheumatology (Oxford)       Date:  2008-04-09       Impact factor: 7.580

4.  Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors.

Authors:  José Luis Rosales Alexander; Jesús Cantero-Hinojosa; Juan Salvatierra; César Magro Checa; Miguel Ángel González-Gay; Enrique Raya Álvarez
Journal:  Joint Bone Spine       Date:  2013-08-09       Impact factor: 4.929

5.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

6.  On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study.

Authors:  Agnete Malm Gulati; Anne Grete Semb; Silvia Rollefstad; Pål R Romundstad; Arthur Kavanaugh; Sasha Gulati; Glenn Haugeberg; Mari Hoff
Journal:  Ann Rheum Dis       Date:  2015-03-26       Impact factor: 19.103

7.  Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis.

Authors:  Oded Kimhi; Dan Caspi; Natan M Bornstein; Nitsan Maharshak; Alexander Gur; Yaron Arbel; Doron Comaneshter; Daphna Paran; Irena Wigler; David Levartovsky; Shlomo Berliner; Ori Elkayam
Journal:  Semin Arthritis Rheum       Date:  2006-10-25       Impact factor: 5.532

Review 8.  Mannheim intima-media thickness consensus.

Authors:  P-J Touboul; M G Hennerici; S Meairs; H Adams; P Amarenco; M Desvarieux; S Ebrahim; M Fatar; R Hernandez Hernandez; S Kownator; P Prati; T Rundek; A Taylor; N Bornstein; L Csiba; E Vicaut; K S Woo; F Zannad
Journal:  Cerebrovasc Dis       Date:  2004-11-02       Impact factor: 2.762

9.  Prevalence of cardiovascular risk factors in patients with psoriatic arthritis.

Authors:  Majed Khraishi; Rana Aslanov; Emmanouil Rampakakis; Clare Pollock; John S Sampalis
Journal:  Clin Rheumatol       Date:  2014-07-18       Impact factor: 2.980

10.  High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors.

Authors:  Carlos Gonzalez-Juanatey; Javier Llorca; Encarnacion Amigo-Diaz; Trinidad Dierssen; Javier Martin; Miguel A Gonzalez-Gay
Journal:  Arthritis Rheum       Date:  2007-08-15
View more
  9 in total

Review 1.  Cardiometabolic Disorders in Psoriatic Disease.

Authors:  Curtis Sobchak; Lihi Eder
Journal:  Curr Rheumatol Rep       Date:  2017-08-26       Impact factor: 4.592

Review 2.  Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

Authors:  Angela McArdle; Stephen Pennington; Oliver FitzGerald
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

3.  Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients.

Authors:  Dionicio A Galarza-Delgado; Jose R Azpiri-Lopez; Iris J Colunga-Pedraza; Natalia Guajardo-Jauregui; Alejandra B Rodriguez-Romero; Salvador Lugo-Perez; Jesus A Cardenas-de la Garza; Rosa I Arvizu-Rivera; Diana E Flores-Alvarado; Octavio Ilizaliturri-Guerra; Gisela Garcia-Arellano; Andrea C Garza-Acosta
Journal:  Clin Rheumatol       Date:  2021-11-26       Impact factor: 2.980

Review 4.  Related Risk Factors and Treatment Management of Psoriatic Arthritis Complicated With Cardiovascular Disease.

Authors:  Zhoulan Zheng; Qianyu Guo; Dan Ma; Xuexue Wang; Chengqiang Zhang; Haiyao Wang; Liyun Zhang; Gailian Zhang
Journal:  Front Cardiovasc Med       Date:  2022-04-06

5.  Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease.

Authors:  Alessandro Giollo; Andrea Dalbeni; Giovanni Cioffi; Federica Ognibeni; Davide Gatti; Luca Idolazzi; Giovanni Orsolini; Pietro Minuz; Maurizio Rossini; Cristiano Fava; Ombretta Viapiana
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

6.  Psoriasis-Related Visceral Adiposity and Arterial Inflammation: A New Adiposity Disease Entity?

Authors:  Thomas H Schindler; Pal Pacher
Journal:  JACC Cardiovasc Imaging       Date:  2017-10-18

Review 7.  Management of inflammatory rheumatic conditions in the elderly.

Authors:  Clément Lahaye; Zuzana Tatar; Jean-Jacques Dubost; Anne Tournadre; Martin Soubrier
Journal:  Rheumatology (Oxford)       Date:  2019-05-01       Impact factor: 7.580

8.  The Oxidative Stress-Induced miR-200c Is Upregulated in Psoriasis and Correlates with Disease Severity and Determinants of Cardiovascular Risk.

Authors:  A Magenta; M D'Agostino; S Sileno; L Di Vito; C Uras; D Abeni; F Martino; F Barillà; S Madonna; C Albanesi; M Napolitano; M C Capogrossi; G Melillo
Journal:  Oxid Med Cell Longev       Date:  2019-12-19       Impact factor: 6.543

9.  Assessment of subclinical atherosclerosis with ankle-brachial index in psoriatic arthritis: A case-control study.

Authors:  Serhad Bilim; Afitap Içağasioğlu; Ayla Akbal; Esen Kasapoğlu; Sıdıka Gürsel
Journal:  Arch Rheumatol       Date:  2021-01-14       Impact factor: 1.472

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.